Discordant High Activated Partial Thromboplastin Time Relative to Anti-Xa Values in Hospitalized Patients is an Independent Risk Factor for Increased 30-day Mortality

被引:0
作者
Jin, Jing [1 ]
Gummidipundi, Santosh [2 ]
Hsu, Joe [2 ]
Sharifi, Husham
Boothroyd, Derek [2 ]
Krishnan, Anandi [3 ,4 ]
Zehnder, James L. [2 ,3 ]
机构
[1] Stanford Hlth Care, Dept Special Coagulat, Clin Labs, Stanford, CA USA
[2] Stanford Univ, Sch Med, Dept Med, Stanford, CA USA
[3] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA USA
[4] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ USA
关键词
activated partial thromboplastin time; anti-factor Xa; concordance; discordant; unfractionated heparin; HEPARIN; AGREEMENT; COLLEGE;
D O I
10.1055/s-0044-1789020
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The activated partial thromboplastin time (aPTT) and anti-factor-Xa levels (anti-Xa) are both used to monitor patients on unfractionated heparin. Our previous study demonstrated that patients with discordant high aPTT relative to anti-Xa had higher rates of mortality and bleeding events. Objective To determine if underlying patient characteristics drive both discordance and adverse outcomes or if discordance is an independent risk factor to adverse outcomes. Methods We analyzed all patients hospitalized at the Stanford Hospital between January 2011 and December 2019 who had simultaneous aPTT and anti-Xa levels performed. From the electronic medical record, we extracted and analyzed 51 patient features including baseline coagulation laboratory results, demographics, values of other common laboratories (basic metabolic panel, complete blood count, etc.), diagnostic procedures, medications, and death. Results A total of 17,728 patients had 78,701 paired aPTT and anti-Xa levels. Patients with discordant aPTT and anti-Xa where aPTT (seconds) was elevated beyond the expected therapeutic range had a higher 30-day mortality (odds ratio [OR]: 2.16, 95% confidence interval [CI]: 1.78-2.63, p < 0.001). Sectioning the patients based on the degree of discordance and whether aPTT or anti-Xa were signaling excess anticoagulation, we found those with an elevated aPTT discordant to their anti-Xa level had the highest odds of death (OR: 2.46, 95% CI: 1.99-3.10) compared with the concordant group. This finding was still present after controlling for patient comorbidity and other laboratory results at hospital admission. Conclusion After controlling for patient features strongly associated with increased mortality in heparinized patients, we identified that the discordant pattern of high aPTT to anti-Xa served as an independent predictor of 30-day all-cause mortality, with a higher degree of discordance associated with increased odds of 30-day mortality.
引用
收藏
页数:9
相关论文
共 16 条
  • [1] Anti-Factor-Xa and Activated Partial Thromboplastin Time Concordance and Outcomes in Adults Undergoing Extracorporeal Membrane Oxygenation: A Secondary Analysis of the Pilot Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation Randomized Trial
    Aubron, Cecile
    Chapalain, Xavier
    Bailey, Michael
    Board, Jasmin
    Buhr, Heidi
    Cartwright, Bruce
    Dennis, Mark
    Hodgson, Carol
    Forrest, Paul
    Mcilroy, David
    Murphy, Deirdre
    Murray, Lynne
    Pellegrino, Vincent
    Pilcher, David
    Sheldrake, Jayne
    Tran, Huyen
    Vallance, Shirley
    Cooper, D. James
    Mcquilten, Zoe
    [J]. CRITICAL CARE EXPLORATIONS, 2023, 5 (11) : E0999
  • [2] Anti-Xa assays: What is their role today in antithrombotic therapy?
    Centeno, Erika Hutt
    Militello, Michael
    Gomes, Marcelo P.
    [J]. CLEVELAND CLINIC JOURNAL OF MEDICINE, 2019, 86 (06) : 417 - 425
  • [3] MONOCLONAL IGM WITH ANTIBODY-LIKE SPECIFICITY FOR PHOSPHOLIPIDS IN A PATIENT WITH LYMPHOMA
    COOPER, MR
    COHEN, HJ
    HUNTLEY, CC
    WAITE, BM
    SPEES, L
    SPURR, CL
    [J]. BLOOD, 1974, 43 (04) : 493 - 504
  • [4] Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time
    Cuker, A.
    Ptashkin, B.
    Konkle, B. A.
    Pipe, S. W.
    Whinna, H. C.
    Zheng, X. L.
    Cines, D. B.
    Pollak, E. S.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (01) : 80 - 86
  • [5] Interference of C-reactive protein with clotting times
    Devreese, Katrien M. J.
    Verfaillie, Charlotte J.
    De Bisschop, Frank
    Delanghe, Joris R.
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2015, 53 (05) : 6141 - 6145
  • [6] Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions
    Faust, Andrew C.
    Kanyer, Dave
    Wittkowsky, Ann K.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (24) : 2037 - 2041
  • [7] Reflecting on eight editions of the American College of Chest Physicians antithrombotic guidelines
    Hirsh, Jack
    Guyatt, Gordon
    Lewis, Sandra Zelman
    [J]. CHEST, 2008, 133 (06) : 1293 - 1295
  • [8] Problems in laboratory monitoring of heparin dosage
    Kitchen, S
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (02) : 397 - 406
  • [9] Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin
    Kovacs, MJ
    Keeney, M
    MacKinnon, K
    Boyle, E
    [J]. CLINICAL AND LABORATORY HAEMATOLOGY, 1999, 21 (01): : 55 - 60
  • [10] Olson JD, 1998, ARCH PATHOL LAB MED, V122, P782